Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006

Inomata, Takayuki; Fukui, Naohito; Kinoshita, Takayuki; Anan, Keisei; Niikura, Naoki; Kawai, Masaaki; Hayashi, Naoki; Tsugawa, Kouichiro; Aogi, Kenjiro; Ishida, Toru; Masuoka, Hideji; Masuda, Shinobu; Iijima, Kotaro; Nakamura, Seigo; Tokuda, Yutaka

doi:10.1007/s12282-015-0646-3

Cited by 11 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, the relatively short follow-up period (median 4.5 years), which limited the power of the survival analysis. Nevertheless, prognostic analyses from this database that have previously been published were relatively consistent with the well-known consensus and clinical outcomes [ 36 – 38 ]. Second, during the study period, trastuzumab (which should exert a favourable effect on HER2-positive breast cancers) had not been widely prescribed as the standard agent and was only partially received.…”

Section: Discussionsupporting

confidence: 52%

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry

Kataoka

Inomata

Tokunaga

et al. 2016

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

PurposeThe aim of this study was to investigate whether young age at onset of breast cancer is an independent prognostic factor in patients from the Japanese Breast Cancer Registry, after adjustment of known clinicopathological prognostic factors.MethodsOf the 53,670 patients registered between 2004 and 2006 and surveyed after a 5-year follow-up prognosis, 25,898 breast cancer patients (48.3 %), who were obtained prognostic data, were examined. Clinicopathological factors were compared between young adult (YA; <35 years), middle-aged adult (MA; 35–50 years), and older adult (OA; >50 years) patients. Five-year disease-free survival (DFS) and overall survival (OS) rates were studied.ResultsYA patients were associated with an advanced TNM stage and aggressive characteristics (e.g. human epidermal growth factor receptor 2 (HER2)-positive or oestrogen receptor (ER)-negative breast cancers) compared to MA and OA patients (P < 0.001). The 5-year DFS and OS rates were 79.4 % and 90.8, 88.5 and 95.0 %, and 87.8 % and 91.6 % for YA, MA, and OA patients, respectively. From the multivariable regression analysis, young age at onset was confirmed as an independent prognostic factor for both DFS (hazard ratio 1.73, 95 % confidence interval 1.42–2.10; P < 0.001) and OS (hazard ratio 1.58, 95 % confidence interval 1.16–2.15; P = 0.004).ConclusionsYoung age at onset is an independent negative prognostic factor in breast cancer. Further studies are required to develop new therapeutic strategies for YA breast cancer patients.Electronic supplementary materialThe online version of this article (doi:10.1007/s10549-016-3984-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 52%

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry

Kataoka

Inomata

Tokunaga

et al. 2016

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

show abstract

“…Breast cancer is divided into four subtypes based Meta-analyses from the Japanese Breast Cancer Society: clinical practice guidelines for breast cancer on hormone receptor (HR) and human epidermal receptor 2 (HER2) statuses. HR-positive breast cancer is the most common subtype, with a frequency of more than 70% worldwide, consistent with Japanese Breast Cancer Society registry data [3,4].…”

Section: Introductionsupporting

confidence: 81%

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis

Shimoi¹,

Sagara

Hara

et al. 2020

Breast Cancer

View full text Add to dashboard Cite

Background In establishing the 2018 Breast Cancer Practice Guidelines of the Japan Breast Cancer Society, we explored the optimal first-line endocrine therapy for advanced postmenopausal hormone receptor-positive breast cancer. Methods We performed a systematic review of relevant reports from randomized-controlled studies published prior to November 2016 found using medical journal search engines. The main outcomes which we evaluated were progression-free survival (PFS), objective response rate (ORR), disease control rate (CBR), and toxicity. Results Four controlled trials comparing aromatase inhibitors (AI) and cyclin-dependent kinase (CDK)4/6 inhibitor combination therapy to AI monotherapy, and two controlled trials comparing anastrozole to fulvestrant 500 mg were analyzed. AI/CDK4/6 inhibitor combination therapy significantly improved PFS (Risk Ratio: 0.67, 95%CI 0.60-0.73), increased ORR (Risk Difference: 0.11, 95% CI 0.07-0.16), and increased CBR (Risk Difference: 0.11, 95% CI 0.07-0.15), compared with AI monotherapy. Patients who received this combination therapy had a higher grade ≥ 3 adverse event rate more than those who received AI monotherapy (Risk Difference: 43%, 95%CI: 0.39-0.47). Fulvestrant 500 mg alone significantly improved PFS (risk ratio: 0.85, 95%CI 0.72-0.98), but ORR and CBR were similar to those of anastrozole alone. Conclusion In the first-line treatment for advanced postmenopausal hormone receptor-positive breast cancer, a combination therapy of CDK4/6 inhibitors and AI showed significant improvement of PFS, ORR, and CBR but with significant increased toxicities compared with AI alone. Fulvestrant 500 mg monotherapy significantly prolonged PFS compared with AI monotherapy. We must wait for the results of the studies with longer follow-up period.

show abstract

“…Invasive ductal carcinoma was the most common histopathological type (75%). Nihon-Yanagi et al showed that the occurrence of mucinous carcinoma (7.8%) and apocrine carcinoma (6.3%) was higher in accessory breast [ 4 ]. Marshall et al further showed a high incidence of infiltrating lobular carcinoma (ILC) (9.5%) in accessory breast [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

“…Marshall et al further showed a high incidence of infiltrating lobular carcinoma (ILC) (9.5%) in accessory breast [ 3 ]. The incidence of these types is high compared to the occurrence in the normal anatomical breast: ILC (3%), mucinous carcinoma (2.9%), apocrine carcinoma (1.1%) [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

Carcinoma of the Accessory Axillary Breast: A Diagnostic Dilemma and a Management Challenge

Sinduja

Kumaran

Sundaramurthi

et al. 2020

Cureus

View full text Add to dashboard Cite

Carcinoma of the accessory axillary breast is uncommon, with an incidence of 0.2 to 0.6%. We report a patient whose biopsy of a suspicious lesion in the axilla present for one year revealed invasive ductal carcinoma (IDC). There was presence of breast tissue and absence of lymphoid tissue in the biopsy, suggesting a breast malignancy. Magnetic resonance mammography was suggestive of the lesion well away from the normal breast, confirming an accessory axillary breast. She was offered wide local excision of the lesion with axillary lymph node dissection and modified radical mastectomy (MRM), and she chose the latter. Her post-operative biopsy showed the involvement of all the 25 lymph nodes harvested. Any suspicious lesion in the axilla should be promptly worked up for malignancy. Accessory axillary breast carcinoma, if confirmed, can be addressed with wide local excision along with axillary lymph node dissection. However, further studies should clarify this and the outcomes.

show abstract

Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006

Cited by 11 publications

References 1 publication

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis

Carcinoma of the Accessory Axillary Breast: A Diagnostic Dilemma and a Management Challenge

Contact Info

Product

Resources

About